Developer docs
API playgroundTry for free, no card

Search company profiles

Caring Cross

Full company profile

uuid00rd298

Namestring
Caring Cross
Legal namestring
Caring Cross
Websiteurl
caringcross.org
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Caring Cross is a 501(c)(3) nonprofit founded in 2012 and headquartered in Gaithersburg, Maryland, focused on developing and deploying affordable CAR-T cell immunotherapies and stem cell gene therapies for cancer, HIV, sickle cell disease, and beta-thalassemia. Its core technology portfolio includes a TriCAR-T cell therapy (with a CD19/CD20/CD22 targeting construct), an anti-HIV duoCAR-T therapy currently in Phase I/IIa clinical trials, an autologous stem cell gene therapy platform for sickle cell disease and beta-thalassemia, and a proprietary T-isopure reagent that simplifies cell therapy manufacturing. The organization also operates an AATM (Advanced Therapy Access Model) network that enables decentralized, point-of-care manufacturing of these therapies in low- and middle-income countries.

The company's business model is built on non-dilutive funding rather than commercial product sales. Revenue is sourced from US federal grants (NCI/NIH, NIST, NIIMBL, ARPA-H), philanthropic support (notably the Bill & Melinda Gates Foundation), technology transfer agreements with international partners (Fiocruz/Brazil), and corporate partnerships. A for-profit CDMO, Vector BioMed, was spun out to manufacture lentiviral vectors for third parties and generate earned revenue tied to the broader Caring Cross ecosystem. Caring Cross serves patients who lack access to high-cost cell and gene therapies, particularly in global health settings, while partnering with ministries of health, academic centers, and hospital networks to localize manufacturing.

Distribution is achieved through technology transfer rather than direct commercialization: international partners adopt the company's manufacturing protocols and reagents to produce therapies locally, supported by Caring Cross's training, quality systems, and process know-how. The model targets a 90%+ cost reduction versus centralized CDMO-produced CAR-T, intending to convert cell and gene therapies from luxury medical interventions into broadly accessible treatments across emerging markets.

Short descriptiontext

Caring Cross is a 501(c)(3) nonprofit developing affordable CAR-T and stem cell gene therapies for cancer, HIV, and sickle cell disease, using technology transfer and decentralized point-of-care manufacturing to serve patients in low- and middle-income countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersGaithersburg, United States
HQ citystring
Gaithersburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell and gene therapy, CAR-T therapy development, lentiviral vector manufacturing, point-of-care biomanufacturing, affordable advanced therapies
Product category
Cell and Gene Therapy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Government Grants and Funding
TypeSubscription Recurring
Description

Caring Cross receives grants from US Federal government (NCI/NIH, NIST, NIIMBL) supporting development of Lentiviral vector and AAV vector technologies, as well as standards development for characterization of critical materials used in advanced therapeutic products.

caringcross.org
2Technology Transfer Agreements
TypeLicensing Royalties
Description

Technology transfer partnerships with government health organizations (e.g., Fiocruz) where Caring Cross provides technology, materials, and training for manufacturing CAR-T cell therapies and lentiviral vectors in exchange for licensing fees and ongoing collaboration.

caringcross.org
3Corporate Partnership Services
TypeHardware Sales
Description

Vector BioMed, a for-profit Benefit Corporation spun out from Caring Cross, provides GMP lentiviral vector manufacturing services to the industry at approximately half the price of competitors, generating revenue that supports Caring Cross's mission.

caringcross.org
4Donations and Charitable Contributions
TypeSubscription Recurring
Description

As a 501(c)(3) non-profit, Caring Cross accepts donations to support its mission of translating plans into actionable steps to make curative approaches to SCD and HIV available in low and middle-income countries.

caringcross.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Commercial CAR-T cell therapy pricing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Current commercial CAR-T cell therapies for lymphoma cost $350,000+ per dose, not including hospital costs. Some patient-specific therapies exceed $3 million.

caringcross.org
2Brazil public health system pricing through Fiocruz partnership
ModelUnit PricingBilling cadenceMulti-year contract
Notes

With local production through Fiocruz partnership, treatment will be available free of charge to the Brazilian population. Cost to Brazilian public health system reduced to 10% of US/European amounts, dropping to approximately $35,000 per dose.

caringcross.org
3AACT Network Academic Medical Center pricing
ModelUnit PricingBilling cadenceMulti-year contract
Notes

AMC network in Spain manufactures anti-CD19 CAR-T cell product for approximately €89,000 (US$95,000). In low-and middle-income countries, AMC manufactured anti-CD19 CAR-T cell product for approximately $35,000, leveraging lower skilled labor costs. Material cost of about $20,000 per product provides sufficient reimbursement under Medicare's $257,958 CAR-T cell therapy product limit (2024).

caringcross.org
4Vector BioMed GMP Lentiviral Vectors
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Vector BioMed manufactures GMP-grade lentiviral vectors at approximately half the price of leading alternatives. Offers custom lentiviral vectors for investigators and generic off-the-shelf CAR vectors.

prweb.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Caring Cross is a 501(c)(3) nonprofit that develops CAR-T cell therapies and stem cell gene therapies for leukemia, lymphoma, HIV, sickle cell disease, and beta-thalassemia. The organization creates enabling technologies, including the proprietary T-isopure reagent and novel lentiviral vector manufacturing processes, and transfers these to partner Academic Medical Centers, government health agencies, and hospitals globally to enable decentralized, point-of-care manufacturing that reduces therapy costs from over $350,000 to approximately $35,000 per dose.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Three HIV trial participants achieved viral suppression lasting 48-92 weeks after single CAR-T infusion
+5 more records
Product overview1 text field

Caring Cross is a 501(c)(3) non-profit developing a portfolio of advanced cell and gene therapies alongside enabling technologies. The core therapeutic products include TriCAR-T cell immunotherapy for leukemia and lymphoma (targeting CD19/CD20/CD22), anti-HIV duoCAR-T cell therapy in clinical trials, and stem cell gene therapies for sickle cell disease and beta-thalassemia. The company also offers proprietary manufacturing reagents (T-isopure™) and has spun out Vector BioMed for GMP lentiviral vector manufacturing. These products are supported by the AATM Network platform enabling decentralized, point-of-care manufacturing at partner Academic Medical Centers worldwide.

Product and service6 records
1TriCAR-T Cell Immunotherapy
CategoryCell Therapy
Description

Multi-targeted CAR-T cell therapy candidate designed to prevent relapse in leukemia and lymphoma patients by simultaneously targeting CD19, CD20, and CD22 surface proteins on cancer cells, addressing the approximately 50% relapse rate seen with single-target anti-CD19 CAR-T therapy.

2Anti-HIV duoCAR-T Cell Therapy
CategoryCell Therapy
Description

CAR-T cell therapy candidate for HIV-1 infection designed to eliminate HIV-infected cells and protect CD4 T cells from HIV infection; in Phase I/IIa clinical trials at UCSF and UC Davis.

3Stem Cell Gene Therapy for Sickle Cell Disease and Beta-Thalassemia
CategoryGene Therapy
Description

Autologous hematopoietic stem cell gene therapy candidates for sickle cell disease and beta-thalassemia using lentiviral vectors. Phase I/IIa clinical trial planned for 2025, with multi-center trials to follow.

4T-isopure Reagent
CategoryManufacturing Reagent
Description

Proprietary reagent that significantly simplifies and reduces the cost of CAR-T cell manufacturing process, increasing robustness and allowing manufacturing from whole blood or apheresis blood product.

5Vector BioMed GMP Lentiviral Vectors
CategoryViral Vector Manufacturing
Description

GMP-grade lentiviral vectors manufactured by Vector BioMed (spun out from Caring Cross) at approximately half the price of competitors; includes custom lentiviral vectors, generic off-the-shelf CAR vectors, and targeted lentiviral vectors.

6Affordable Advanced Therapies Manufacturing (AATM) Network
CategoryManufacturing Network
Description

Global network of Academic Medical Centers collaborating with Caring Cross to enable point-of-care GMP manufacturing capabilities, accelerate research and clinical development, and improve patient access to affordable CAR-T and other advanced therapies.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Nigeria Ministry of Health
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2026-05-06
Description

Nigeria's government reaffirmed commitment to advancing health innovation through partnerships with Caring Cross, focusing on solutions such as CAR T-cell therapy to improve health outcomes. Initiative aims to leverage Nigeria's biodiversity and develop local medical solutions addressing diseases like sickle cell and blood cancers.

leadership.ng
Strategic tierSecondaryTypeTechnology or IntegrationAnnounced on2026-03-31
Description

Partnership with Trenchant BioSystems and University of Massachusetts Chan Medical School to develop automated manufacturing platform for gene-modified HSC therapies targeting sickle cell disease and beta thalassemia. Leverages AutoCell platform with microbubble separation technology. Plans FDA INTERACT meeting Q1 2027 and Phase I/II trial later that year.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

BioCurie awarded up to $9.3 million from ARPA-H to develop AI platform for scalable gene therapy manufacturing. Caring Cross is part of consortium including St. Jude Children's Research Hospital, Center for Breakthrough Medicines, and University City Science Center. Platform aims to replace trial-and-error process development with computational modeling.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-25
Description

Strategic partnership to develop and implement affordable, scalable cell and gene therapy solutions for underserved populations in India. Collaboration establishes decentralized therapeutic manufacturing and advances TriCAR-T cell therapies for Leukemia, Lymphoma, Sickle Cell Disease, Thalassemia, and various cancers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-10
Description

Partnership to establish local manufacturing of CAR-T and stem cell gene therapies in MENA region, reducing treatment costs by up to 90%. Initial focus on leukemia and lymphoma with plans to expand to other treatments. GMP facility in Abu Dhabi to process up to 200 samples simultaneously, announced at Abu Dhabi Global Health Week.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-21
Description

Partnership to enable place-of-care GMP manufacturing by combining Germfree's advanced mobile cleanroom technology with Caring Cross's manufacturing expertise and CGT products. Addresses limitations of CGTs being expensive, time-consuming to produce, and only available in affluent regions. Builds on three-year collaboration including Fiocruz pilot project.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-26
Description

Technology transfer agreement with Fiocruz and Brazilian Ministry of Health to develop, manufacture, and commercialize CAR-T cell therapies for Brazilian population and Latin America. Caring Cross provides technology, materials, and training to Bio-Manguinhos for CAR-T and lentiviral vector manufacturing. Treatment cost reduced to approximately $35,000 per dose (10% of US/Europe pricing).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vector BioMed, founded as a for-profit Benefit Corporation, operates as a leading viral vector manufacturing CDMO. Established on novel lentiviral vector technology developed at Caring Cross. Offers GMP lentiviral vectors at half the price of competitors, custom vectors, generic off-the-shelf CAR vectors, and targeted lentiviral vectors for in vivo gene therapy. Manufacturing facilities in Gaithersburg, Maryland.

Strategic tierSecondaryTypeTechnology or Integration
Description

Collaboration provides technologies and solutions supporting Caring Cross's mission to enable affordability and accessibility of CAR-T cell therapies. Cytiva provides equipment including Sepax C-Pro, VIA Thaw, and VIA Freeze instruments to streamline CAR-T manufacturing processes, reduce processing times, and minimize contamination risks.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Caring Cross working with BMGF to develop lentiviral vector manufacturing processes to decrease cost of gene therapy delivery. Project focuses on developing lentiviral vectors that can be used directly as injectable medicines for treatment of HIV and Sickle Cell Disease.

11Global Gene Therapy Initiative (GGTI)
Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Caring Cross is a founding member of GGTI, a working group holding weekly meetings to discuss affordability and access of gene therapies globally. Provides knowledge transfer on technology and access issues, strategizes partnerships to improve access in low-and middle-income countries.

caringcross.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage gene-editing company developing CAR-T cell therapies (UCART) using TALEN-based genome editing. Comparable as a CAR-T platform developer with active programs in leukemia/lymphoma, similar to Caring Cross's TriCAR-T multi-targeting approach.

2bluebird bio
TypeDirect peer
Description

Gene therapy company commercializing Lyfgenia for sickle cell disease and beti-cel for beta-thalassemia. Directly competes with Caring Cross in SCD/BT gene therapy, though at commercial >$2M price points rather than the affordable-access positioning.

TypeDirect peer
Description

Clinical-stage CAR-T company developing allogeneic ("off-the-shelf") CAR-T therapies for hematologic malignancies and solid tumors. Operates in the same CAR-T competitive arena as Caring Cross with overlapping indications in leukemia and lymphoma.

4Tmunity Therapeutics
TypeDirect peer
Description

University of Pennsylvania spin-out developing CAR-T cell therapies for cancer and other diseases. Most directly comparable to Caring Cross's TriCAR-T program given its academic-origin CAR-T focus, though operating as a private venture-backed company.

TypeDirect peer
Description

Cell therapy company developing engineered TCR therapies for solid tumors and hematologic malignancies. Comparable as a cell therapy developer targeting blood cancers with engineered immune cell platforms.

TypeEmerging player
Description

Co-developed Casgevy (exa-cel), the first FDA-approved CRISPR-based therapy for sickle cell disease and beta-thalassemia with Vertex. Overlaps with Caring Cross's SCD/BT stem cell gene therapy program but uses ex vivo CRISPR editing rather than lentiviral delivery.

TypeBroad incumbent
Description

Commercializer of Kymriah, the first FDA-approved CAR-T therapy (using the lentiviral vector originally developed by Caring Cross's co-founder). Broad incumbent in commercial CAR-T and a historical anchor reference point for the field.

TypeBroad incumbent
Description

Through its partnership with CRISPR Therapeutics, commercializes Casgevy for sickle cell disease and beta-thalassemia, directly competing in the same indications Caring Cross targets via lower-cost lentiviral gene therapy.

TypeBroad incumbent
Description

Through Kite Pharma, commercializes Yescarta and Tecartus CAR-T therapies for lymphoma and ALL. Represents the established commercial CAR-T landscape Caring Cross aims to disrupt via point-of-care manufacturing cost reduction.

10Bristol-Myers Squibb
TypeBroad incumbent
Description

Markets Breyanzi and Abecma CAR-T therapies for lymphoma and multiple myeloma through the Celgene/Juno acquisition. Represents commercial CAR-T competition Caring Cross's TriCAR-T is positioned against in hematologic malignancies.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Caring Cross

Cell and Gene Therapycaringcross.org

Caring Cross is a 501(c)(3) nonprofit developing affordable CAR-T and stem cell gene therapies for cancer, HIV, and sickle cell disease, using technology transfer and decentralized point-of-care manufacturing to serve patients in low- and middle-income countries.

What Caring Cross does

Caring Cross is a 501(c)(3) nonprofit founded in 2012 and headquartered in Gaithersburg, Maryland, focused on developing and deploying affordable CAR-T cell immunotherapies and stem cell gene therapies for cancer, HIV, sickle cell disease, and beta-thalassemia. Its core technology portfolio includes a TriCAR-T cell therapy (with a CD19/CD20/CD22 targeting construct), an anti-HIV duoCAR-T therapy currently in Phase I/IIa clinical trials, an autologous stem cell gene therapy platform for sickle cell disease and beta-thalassemia, and a proprietary T-isopure reagent that simplifies cell therapy manufacturing. The organization also operates an AATM (Advanced Therapy Access Model) network that enables decentralized, point-of-care manufacturing of these therapies in low- and middle-income countries.

The company's business model is built on non-dilutive funding rather than commercial product sales. Revenue is sourced from US federal grants (NCI/NIH, NIST, NIIMBL, ARPA-H), philanthropic support (notably the Bill & Melinda Gates Foundation), technology transfer agreements with international partners (Fiocruz/Brazil), and corporate partnerships. A for-profit CDMO, Vector BioMed, was spun out to manufacture lentiviral vectors for third parties and generate earned revenue tied to the broader Caring Cross ecosystem. Caring Cross serves patients who lack access to high-cost cell and gene therapies, particularly in global health settings, while partnering with ministries of health, academic centers, and hospital networks to localize manufacturing.

Distribution is achieved through technology transfer rather than direct commercialization: international partners adopt the company's manufacturing protocols and reagents to produce therapies locally, supported by Caring Cross's training, quality systems, and process know-how. The model targets a 90%+ cost reduction versus centralized CDMO-produced CAR-T, intending to convert cell and gene therapies from luxury medical interventions into broadly accessible treatments across emerging markets.

Caring Cross firmographics

Firmographics
Name
Caring Cross
Legal name
Caring Cross
Website
https://caringcross.org
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Caring Cross is a 501(c)(3) nonprofit developing affordable CAR-T and stem cell gene therapies for cancer, HIV, and sickle cell disease, using technology transfer and decentralized point-of-care manufacturing to serve patients in low- and middle-income countries.
Ownership category
akta.pro rank

Where Caring Cross is headquartered

Location

Headquarters

HQ city
Gaithersburg
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Caring Cross business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Government Grants and Funding: Caring Cross receives grants from US Federal government (NCI/NIH, NIST, NIIMBL) supporting development of Lentiviral vector and AAV vector technologies, as well as standards development for characterization of critical materials used in advanced therapeutic products.
  2. Technology Transfer Agreements: Technology transfer partnerships with government health organizations (e.g., Fiocruz) where Caring Cross provides technology, materials, and training for manufacturing CAR-T cell therapies and lentiviral vectors in exchange for licensing fees and ongoing collaboration.
  3. Corporate Partnership Services: Vector BioMed, a for-profit Benefit Corporation spun out from Caring Cross, provides GMP lentiviral vector manufacturing services to the industry at approximately half the price of competitors, generating revenue that supports Caring Cross's mission.
  4. Donations and Charitable Contributions: As a 501(c)(3) non-profit, Caring Cross accepts donations to support its mission of translating plans into actionable steps to make curative approaches to SCD and HIV available in low and middle-income countries.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractCommercial CAR-T cell therapy pricing
Unit PricingMulti-year contractBrazil public health system pricing through Fiocruz partnership
Unit PricingMulti-year contractAACT Network Academic Medical Center pricing
Unit PricingPay-as-you-goVector BioMed GMP Lentiviral Vectors

Go-to-market motion2 records

Distribution channels6 records

Marketing channels8 records

Caring Cross product offering

Product offering

Core offering

Caring Cross is a 501(c)(3) nonprofit that develops CAR-T cell therapies and stem cell gene therapies for leukemia, lymphoma, HIV, sickle cell disease, and beta-thalassemia. The organization creates enabling technologies, including the proprietary T-isopure reagent and novel lentiviral vector manufacturing processes, and transfers these to partner Academic Medical Centers, government health agencies, and hospitals globally to enable decentralized, point-of-care manufacturing that reduces therapy costs from over $350,000 to approximately $35,000 per dose.

Product overview

Caring Cross is a 501(c)(3) non-profit developing a portfolio of advanced cell and gene therapies alongside enabling technologies. The core therapeutic products include TriCAR-T cell immunotherapy for leukemia and lymphoma (targeting CD19/CD20/CD22), anti-HIV duoCAR-T cell therapy in clinical trials, and stem cell gene therapies for sickle cell disease and beta-thalassemia. The company also offers proprietary manufacturing reagents (T-isopure™) and has spun out Vector BioMed for GMP lentiviral vector manufacturing. These products are supported by the AATM Network platform enabling decentralized, point-of-care manufacturing at partner Academic Medical Centers worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • TriCAR-T Cell Immunotherapy Multi-targeted CAR-T cell therapy candidate designed to prevent relapse in leukemia and lymphoma patients by simultaneously targeting CD19, CD20, and CD22 surface proteins on cancer cells, addressing the approximately 50% relapse rate seen with single-target anti-CD19 CAR-T therapy.
  • Anti-HIV duoCAR-T Cell Therapy CAR-T cell therapy candidate for HIV-1 infection designed to eliminate HIV-infected cells and protect CD4 T cells from HIV infection; in Phase I/IIa clinical trials at UCSF and UC Davis.
  • Stem Cell Gene Therapy for Sickle Cell Disease and Beta-Thalassemia Autologous hematopoietic stem cell gene therapy candidates for sickle cell disease and beta-thalassemia using lentiviral vectors. Phase I/IIa clinical trial planned for 2025, with multi-center trials to follow.
  • T-isopure Reagent Proprietary reagent that significantly simplifies and reduces the cost of CAR-T cell manufacturing process, increasing robustness and allowing manufacturing from whole blood or apheresis blood product.
  • Vector BioMed GMP Lentiviral Vectors GMP-grade lentiviral vectors manufactured by Vector BioMed (spun out from Caring Cross) at approximately half the price of competitors; includes custom lentiviral vectors, generic off-the-shelf CAR vectors, and targeted lentiviral vectors.
  • Affordable Advanced Therapies Manufacturing (AATM) Network Global network of Academic Medical Centers collaborating with Caring Cross to enable point-of-care GMP manufacturing capabilities, accelerate research and clinical development, and improve patient access to affordable CAR-T and other advanced therapies.

Quantifiable outcome

  • Three HIV trial participants achieved viral suppression lasting 48-92 weeks after single CAR-T infusion
  • +5 more outcomes

Companies that use Caring Cross

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Caring Cross technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Caring Cross partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered secondary and core.

  • Nigeria Ministry of HealthsecondaryStrategic or Co-development Partner · 6 May 2026Nigeria's government reaffirmed commitment to advancing health innovation through partnerships with Caring Cross, focusing on solutions such as CAR T-cell therapy to improve health outcomes. Initiative aims to leverage Nigeria's biodiversity and develop local medical solutions addressing diseases like sickle cell and blood cancers.
  • Trenchant BioSystemssecondaryTechnology or Integration · 31 March 2026Partnership with Trenchant BioSystems and University of Massachusetts Chan Medical School to develop automated manufacturing platform for gene-modified HSC therapies targeting sickle cell disease and beta thalassemia. Leverages AutoCell platform with microbubble separation technology. Plans FDA INTERACT meeting Q1 2027 and Phase I/II trial later that year.
  • BioCuriesecondaryStrategic or Co-development Partner · 12 March 2026BioCurie awarded up to $9.3 million from ARPA-H to develop AI platform for scalable gene therapy manufacturing. Caring Cross is part of consortium including St. Jude Children's Research Hospital, Center for Breakthrough Medicines, and University City Science Center. Platform aims to replace trial-and-error process development with computational modeling.
  • Amrita Research Center Delhi and Amrita Vishwa VidyapeethamcoreStrategic or Co-development Partner · 25 November 2025Strategic partnership to develop and implement affordable, scalable cell and gene therapy solutions for underserved populations in India. Collaboration establishes decentralized therapeutic manufacturing and advances TriCAR-T cell therapies for Leukemia, Lymphoma, Sickle Cell Disease, Thalassemia, and various cancers.
  • Burjeel HoldingscoreStrategic or Co-development Partner · 10 April 2025Partnership to establish local manufacturing of CAR-T and stem cell gene therapies in MENA region, reducing treatment costs by up to 90%. Initial focus on leukemia and lymphoma with plans to expand to other treatments. GMP facility in Abu Dhabi to process up to 200 samples simultaneously, announced at Abu Dhabi Global Health Week.
  • GermfreecoreStrategic or Co-development Partner · 21 August 2024Partnership to enable place-of-care GMP manufacturing by combining Germfree's advanced mobile cleanroom technology with Caring Cross's manufacturing expertise and CGT products. Addresses limitations of CGTs being expensive, time-consuming to produce, and only available in affluent regions. Builds on three-year collaboration including Fiocruz pilot project.
  • Fundação Oswaldo Cruz (Fiocruz)coreStrategic or Co-development Partner · 26 March 2024Technology transfer agreement with Fiocruz and Brazilian Ministry of Health to develop, manufacture, and commercialize CAR-T cell therapies for Brazilian population and Latin America. Caring Cross provides technology, materials, and training to Bio-Manguinhos for CAR-T and lentiviral vector manufacturing. Treatment cost reduced to approximately $35,000 per dose (10% of US/Europe pricing).
  • Vector BioMedcoreStrategic or Co-development PartnerVector BioMed, founded as a for-profit Benefit Corporation, operates as a leading viral vector manufacturing CDMO. Established on novel lentiviral vector technology developed at Caring Cross. Offers GMP lentiviral vectors at half the price of competitors, custom vectors, generic off-the-shelf CAR vectors, and targeted lentiviral vectors for in vivo gene therapy. Manufacturing facilities in Gaithersburg, Maryland.
  • CytivasecondaryTechnology or IntegrationCollaboration provides technologies and solutions supporting Caring Cross's mission to enable affordability and accessibility of CAR-T cell therapies. Cytiva provides equipment including Sepax C-Pro, VIA Thaw, and VIA Freeze instruments to streamline CAR-T manufacturing processes, reduce processing times, and minimize contamination risks.
  • Bill and Melinda Gates Foundation (BMGF)coreStrategic or Co-development PartnerCaring Cross working with BMGF to develop lentiviral vector manufacturing processes to decrease cost of gene therapy delivery. Project focuses on developing lentiviral vectors that can be used directly as injectable medicines for treatment of HIV and Sickle Cell Disease.
  • Global Gene Therapy Initiative (GGTI)secondaryStrategic or Co-development PartnerCaring Cross is a founding member of GGTI, a working group holding weekly meetings to discuss affordability and access of gene therapies globally. Provides knowledge transfer on technology and access issues, strategizes partnerships to improve access in low-and middle-income countries.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Caring Cross competitors and assessment

Company assessment

Direct peers

  • Cellectis: Clinical-stage gene-editing company developing CAR-T cell therapies (UCART) using TALEN-based genome editing. Comparable as a CAR-T platform developer with active programs in leukemia/lymphoma, similar to Caring Cross's TriCAR-T multi-targeting approach.
  • bluebird bio: Gene therapy company commercializing Lyfgenia for sickle cell disease and beti-cel for beta-thalassemia. Directly competes with Caring Cross in SCD/BT gene therapy, though at commercial >$2M price points rather than the affordable-access positioning.
  • Allogene Therapeutics: Clinical-stage CAR-T company developing allogeneic ("off-the-shelf") CAR-T therapies for hematologic malignancies and solid tumors. Operates in the same CAR-T competitive arena as Caring Cross with overlapping indications in leukemia and lymphoma.
  • Tmunity Therapeutics: University of Pennsylvania spin-out developing CAR-T cell therapies for cancer and other diseases. Most directly comparable to Caring Cross's TriCAR-T program given its academic-origin CAR-T focus, though operating as a private venture-backed company.
  • Adaptimmune: Cell therapy company developing engineered TCR therapies for solid tumors and hematologic malignancies. Comparable as a cell therapy developer targeting blood cancers with engineered immune cell platforms.

Emerging players

  • CRISPR Therapeutics: Co-developed Casgevy (exa-cel), the first FDA-approved CRISPR-based therapy for sickle cell disease and beta-thalassemia with Vertex. Overlaps with Caring Cross's SCD/BT stem cell gene therapy program but uses ex vivo CRISPR editing rather than lentiviral delivery.

Broad incumbents

  • Novartis: Commercializer of Kymriah, the first FDA-approved CAR-T therapy (using the lentiviral vector originally developed by Caring Cross's co-founder). Broad incumbent in commercial CAR-T and a historical anchor reference point for the field.
  • Vertex Pharmaceuticals: Through its partnership with CRISPR Therapeutics, commercializes Casgevy for sickle cell disease and beta-thalassemia, directly competing in the same indications Caring Cross targets via lower-cost lentiviral gene therapy.
  • Gilead Sciences (Kite Pharma): Through Kite Pharma, commercializes Yescarta and Tecartus CAR-T therapies for lymphoma and ALL. Represents the established commercial CAR-T landscape Caring Cross aims to disrupt via point-of-care manufacturing cost reduction.
  • Bristol-Myers Squibb: Markets Breyanzi and Abecma CAR-T therapies for lymphoma and multiple myeloma through the Celgene/Juno acquisition. Represents commercial CAR-T competition Caring Cross's TriCAR-T is positioned against in hematologic malignancies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Caring Cross social profiles

Digital presence

Caring Cross financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Caring Cross leadership team

Management profile

Number of profiles

Profiles2 records

Caring Cross subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Caring Cross funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Caring Cross M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Caring Cross

What does Caring Cross do?

Caring Cross is a 501(c)(3) nonprofit that develops CAR-T cell therapies and stem cell gene therapies for leukemia, lymphoma, HIV, sickle cell disease, and beta-thalassemia. The organization creates enabling technologies, including the proprietary T-isopure reagent and novel lentiviral vector manufacturing processes, and transfers these to partner Academic Medical Centers, government health agencies, and hospitals globally to enable decentralized, point-of-care manufacturing that reduces therapy costs from over $350,000 to approximately $35,000 per dose.

Is Caring Cross a public or private company?

Caring Cross is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Caring Cross founded?

Caring Cross was founded in 2019. It employs 11 to 50 people.

Where is Caring Cross based?

Caring Cross is headquartered in Gaithersburg, United States, in the North America region.

How does Caring Cross make money?

Four revenue lines are on record. Government Grants and Funding is the primary driver. The others are technology Transfer Agreements, corporate Partnership Services and donations and Charitable Contributions.

Who are Caring Cross's main competitors?

Direct peers on record are Cellectis, bluebird bio, Allogene Therapeutics, Tmunity Therapeutics and Adaptimmune. CRISPR Therapeutics is listed as an emerging player. Broad incumbents are Novartis, Vertex Pharmaceuticals, Gilead Sciences (Kite Pharma) and Bristol-Myers Squibb.

Does Caring Cross have an API?

No public API is recorded for Caring Cross.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AP NewsSmall study hints that revving up immune cells might help fight HIVResearchers reported that a single dose of CAR-T cells suppressed HIV in two patients for nearly a year and two years, without their usual medicines. The study, led by Dr. Steven Deeks, found no serious side effects, but larger trials are needed to confirm long-term efficacy.PR NewswireCaring Cross Announces Promising Clinical Data with Single-Dose anti-HIV CAR-T Cell TherapyCaring Cross presented early clinical data from a Phase I/IIa trial of anti-HIV CAR-T cell therapy at ASGCT, where two participants maintained undetectable viral loads after stopping antiretroviral therapy. The trial involved nine participants, with no serious adverse events, and suggests early ART initiation may enable durable control. The study is ongoing, with future studies exploring modifications.The New York TimesA Single Infusion Could Suppress H.I.V. for Years, Study SuggestsA study led by researchers at the University of California, San Francisco found that a single infusion of engineered immune cells enabled some H.I.V. patients to suppress the virus to undetectable levels, with one participant maintaining control for nearly two years. The research, conducted by the nonprofit Caring Cross, showed that three participants treated early in their infection achieved viral suppression lasting 48 to 92 weeks after stopping antiretroviral drugs, while three participants with longer-standing infection did not respond. The treatment approach, adapted from cancer CAR-T therapy, remains years or decades from widespread availability but represents a proof-of-concept milestone for a potential functional cure affecting over 40 million people living with H.I.V. worldwide.Leadership NewsNigeria Targets Breakthrough In Gene Therapy Through Global Health PartnershipsNigeria's government reaffirmed its commitment to advancing health innovation through partnerships with international organizations like Caring Cross, focusing on solutions such as CAR T-cell therapy to improve health outcomes. The initiative aims to leverage Nigeria’s biodiversity and develop local medical solutions, addressing diseases like sickle cell and blood cancers with a broader goal of strengthening health systems in Africa.GenengnewsAdvancing the Manufacture of Patient Accessible Cell and Gene Therapies at Place-of-CareA partnership between Trenchant BioSystems, the University of Massachusetts Chan Medical School, and Caring Cross has been formed to develop an automated manufacturing platform for gene-modified hematopoietic stem cell therapies targeting sickle cell disease and beta thalassemia. The collaboration leverages Trenchant BioSystems' AutoCell platform, which uses microbubble separation technology to reduce the footprint and costs of cell and gene therapy manufacturing compared to conventional methods. The alliance plans to seek FDA feedback through an INTERACT meeting in the first quarter of 2027 and launch a Phase I/II clinical trial later that year.PR NewswireCaring Cross and Amrita Research Center Delhi, Amrita Vishwa Vidyapeetham Announce Strategic Partnership to Advance Affordable Cell and Gene Therapies for Underserved Populations Across IndiaCaring Cross, a U.S.-based non-profit, announced a strategic partnership with the Amrita Research Center Delhi and Amrita Vishwa Vidyapeetham to develop and implement affordable, scalable cell and gene therapy solutions for underserved populations in India. The collaboration will establish decentralized therapeutic manufacturing and advance TriCAR-T cell therapies for Leukemia, Lymphoma, Sickle Cell Disease, Thalassemia, and various cancers, aiming to reduce costs at the point of care. The partnership seeks to create a replicable model for equitable advanced therapy solutions addressing India's substantial burden of hereditary blood disorders and cancers among lower-income communities.CaringcrossGlobal Gene Therapy Initiative Impact ProjectCaring Cross is partnering with the Bill and Melinda Gates Foundation to develop Lentiviral vector manufacturing processes aimed at reducing the cost of gene therapies for HIV and Sickle Cell Disease. As a founding member of the Global Gene Therapy Initiative, Caring Cross collaborates on strategies to improve equitable access to advanced medicines in low- and middle-income countries.CaringcrossGlobal Gene Therapy Initiative Impact ProjectCaring Cross is collaborating with select Academic Medical Centers (AMC) to enhance the research and clinical development of affordable CAR-T and other advanced therapies globally. The initiative demonstrates the potential for reduced costs in CAR-T cell therapies, with pricing referenced from a network in Spain and a low- and middle-income country, emphasizing accessibility particularly for patients in underserved regions. The project aims to establish a global AMC network to improve patient access to sustainable gene therapy treatments.